A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline‐containing neoadjuvant chemotherapy for breast cancer

Abstract

Our prognostic model could easily discriminate patients with different risks of experiencing an event or death, which could allow physicians to tailor treatment strategies specifically and individually.